Sarepta’s $852m Summit Collaboration Could Enable DMD Drug Combinations

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Sarepta committed up to $562m for European and other rights to Summit’s lead DMD drug candidate ezutromid plus additional fees for other utrophin modulators in a deal announced on Oct. 4 that could enable combination therapy regimens.

Watch gears up close

Sarepta Therapeutics Inc. and Summit Therapeutics PLC entered into an $852m collaboration that could lead to one of the first combination therapy regimens for the treatment of Duchenne muscular dystrophy (DMD) following US FDA approval of Sarepta’s Exondys 51 (eteplirsen), the first medicine ever approved to treat the rare, degenerative, neuromuscular disease.

Cambridge, Massachusetts-based Sarepta paid $40m up front and committed up to $522m in development, regulatory and commercial milestone fees plus...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains